The use of fasting vs. non-fasting triglyceride concentration for estimating the prevalence of high LDL-cholesterol and metabolic syndrome in population surveys

被引:14
|
作者
Sundvall, Jouko [1 ]
Leiviska, Jaana [1 ]
Laatikainen, Tiina [1 ]
Peltonen, Markku [1 ]
Salomaa, Veikko [1 ]
Vanhala, Mauno [2 ,3 ]
Korpi-Hyovalti, Eeva [4 ]
Lauronen, Jukka [1 ]
Alfthan, Georg [1 ]
机构
[1] Natl Inst Hlth & Welf, Dept Chron Dis Prevent, Helsinki, Finland
[2] Cent Finland Cent Hosp, Unit Family Practice, Jyvaskyla, Finland
[3] Univ Eastern Finland, Dept Publ Hlth & Clin Nutr, Kuopio, Finland
[4] Seinajoki Cent Hosp, Dept Internal Med, Seinajoki, Finland
来源
基金
芬兰科学院;
关键词
CORONARY-HEART-DISEASE; CARDIOVASCULAR RISK-FACTORS; SYSTEMATIC-ERROR; MEN; MANAGEMENT; TRACKING; LIPIDS; WOMEN;
D O I
10.1186/1471-2288-11-63
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: For practical reasons it is not easy to obtain fasting samples in large population health surveys. Non-fasting triglyceride (Tg) values are difficult to interpret. The authors compared the accuracy of statistically corrected non-fasting Tg values with true fasting values and estimated the misclassification of subjects with high low-density lipoprotein cholesterol (LDL-C) and the metabolic syndrome. Methods: Non-fasting blood was obtained from a population-based sample of 4282 individuals aged 24-75 years in the National FINRISK 2007 Study. Fasting blood samples were drawn from the same persons 3 months later. Non-fasting serum Tg values were converted into fasting values using previously published formula. LDL-C was calculated and classification of the metabolic syndrome was carried out according to three different latest guidelines. Results: The median (25(th), 75th percentile) non-fasting serum Tg concentration was 1.18 (0.87, 1.72) mmol/L and after postprandial correction 1.06 (0.78, 1.52) mmol/L. The true-fasting serum Tg concentration was 1.00 (0.75, 1.38) mmol/L (P < 0.001) vs. non-fasting and corrected value. Bias of the corrected value was +5.9% compared with the true-fasting Tg. Of the true fasting subjects, 56.4% had LDL-C >= 3.00 mmol/L. When calculated using non-fasting serum Tg, the prevalence of high LDL-C was 51.3% and using statistically corrected Tg it was 54.8%. The prevalence of metabolic syndrome was 35.5% among fully fasted persons and among non-fasting subjects 39.7%, which after statistical correction of Tg decreased to 37.6% (P < 0.001 for all comparisons). Conclusions: Correction of non-fasting serum Tg to fasting values plays a minor role in population studies but nevertheless reduces misclassification of calculated high LDL-C from 5.1 to 1.6% and the metabolic syndrome from 4.2 to 2.1%.
引用
收藏
页数:6
相关论文
共 10 条
  • [1] The use of fasting vs. non-fasting triglyceride concentration for estimating the prevalence of high LDL-cholesterol and metabolic syndrome in population surveys
    Jouko Sundvall
    Jaana Leiviskä
    Tiina Laatikainen
    Markku Peltonen
    Veikko Salomaa
    Mauno Vanhala
    Eeva Korpi-Hyövälti
    Jukka Lauronen
    Georg Alfthan
    [J]. BMC Medical Research Methodology, 11
  • [2] The effect of fasting vs. non-fasting samples on four homogenous LDL-cholesterol assays.
    Anderson, FP
    Jayne, EC
    Ethridge, SF
    Miller, WG
    Waymack, PP
    Karageorge, LS
    [J]. CLINICAL CHEMISTRY, 2000, 46 (06) : A106 - A106
  • [3] Assessment of three equations to calculate plasma LDL cholesterol concentration in fasting and non-fasting hypertriglyceridemic patients
    Vasse, Josephine
    Lassartesse, Audrey
    Marmontel, Oriane
    Charriere, Sybil
    Bouveyron, Caroline
    Marrie, Nathanael
    Moulin, Philippe
    Di Filippo, Mathilde
    [J]. CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2024, 62 (02) : 270 - 279
  • [4] Associations of a metabolic syndrome severity score with coronary heart disease and diabetes in fasting vs. non-fasting individuals
    DeBoer, Mark D.
    Filipp, Stephanie L.
    Gurka, Matthew J.
    [J]. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2020, 30 (01) : 92 - 98
  • [5] Tesaglitazar reduced the prevalence of metabolic syndrome and impaired fasting glucose in an insulin-resistant, non-diabetic population
    Schuster, HM
    Fagerberg, B
    Edwards, S
    Halmos, T
    Lopatynski, J
    Stender, S
    Birketvedt, GS
    Tonstad, S
    Öhman, P
    Gause-Nilsson, I
    [J]. DIABETES, 2005, 54 : A152 - A152
  • [6] Prevalence of metabolic syndrome and the comparison of fasting plasma glucose and HbA1c as the glycemic criterion for MetS definition in non-diabetic population in Ghana
    Annani-Akollor, Max Efui
    Laing, Edwin Ferguson
    Osei, Henry
    Mensah, Evans
    Owiredu, Eddie-Williams
    Afranie, Bright Oppong
    Anto, Enoch Odame
    [J]. DIABETOLOGY & METABOLIC SYNDROME, 2019, 11 (1):
  • [7] Prevalence of metabolic syndrome and the comparison of fasting plasma glucose and HbA1c as the glycemic criterion for MetS definition in non-diabetic population in Ghana
    Max Efui Annani-Akollor
    Edwin Ferguson Laing
    Henry Osei
    Evans Mensah
    Eddie-Williams Owiredu
    Bright Oppong Afranie
    Enoch Odame Anto
    [J]. Diabetology & Metabolic Syndrome, 11
  • [8] USE OF THE PLASMA TRIGLYCERIDE/HIGH-DENSITY LIPOPROTEIN CHOLESTEROL CONCENTRATION RATIO VERSUS METABOLIC SYNDROME CRITERIA TO IDENTIFYING CARDIOVASCULAR DISEASE RISK AND OUTCOME
    Gharipour, M.
    Sadeghi, M.
    Diantkhah, M.
    Sarrafzadegan, N.
    [J]. JOURNAL OF HYPERTENSION, 2015, 33 : E274 - E274
  • [9] Identifying cardiovascular disease risk and outcome: use of the plasma triglyceride/high-density lipoprotein cholesterol concentration ratio versus metabolic syndrome criteria
    Salazar, M. R.
    Carbajal, H. A.
    Espeche, W. G.
    Aizpurua, M.
    Sisnieguez, C. E. Leiva
    March, C. E.
    Balbin, E.
    Stavile, R. N.
    Reaven, G. M.
    [J]. JOURNAL OF INTERNAL MEDICINE, 2013, 273 (06) : 595 - 601
  • [10] High prevalence of the metabolic syndrome in obese and non-obese cherokee adolescent is characterized by elevated systolic blood pressure, low HDL-C and association with fasting insulin levels
    Blackett, PR
    Blevins, KS
    Stoddart, M
    Quintana, E
    Lee, ET
    [J]. DIABETES, 2005, 54 : A449 - A449